Product Detailed Description

Liposomal zeaxanthin 40% — High Bioavailability Macular Health Supplement

Product Overview

liposomal Zeaxanthin 40% is a premium-grade dietary supplement ingredient delivering zeaxanthin in an advanced liposomal delivery system. Zeaxanthin (CAS 144-68-3), also known as (3R,3′R)-β,β-carotene-3,3′-diol, is a naturally occurring xanthophyll carotenoid with the molecular formula C₄₀H₅₆O₂ and a molecular weight of 568.87 g/mol. It is a yellow-orange pigment synthesized exclusively by plants and microorganisms; humans cannot synthesize it and must acquire it through dietary intake.

Zeaxanthin is selectively concentrated in the fovea, the center of the human macula, where it forms the macular pigment alongside lutein and meso-zeaxanthin. This pigment serves as a natural optical filter that absorbs high-energy blue light (wavelengths 400–500 nm), protecting the underlying photoreceptor cells from photo-oxidative damage. Zeaxanthin was first isolated from corn (Zea mays) and is commercially extracted from marigold (Tagetes erecta L.) flower petals, the same botanical source used for lutein.

Why Liposomal Technology?

Native zeaxanthin presents significant formulation challenges. The compound is practically insoluble in water and only sparingly soluble in chloroform, exhibiting extremely low aqueous solubility. It is chemically unstable to light, heat, and oxidative stress, and its oral bioavailability is low and highly variable. These factors significantly limit its stability in supplement formulations and its absorption in the gastrointestinal tract.

Liposomal encapsulation provides four critical advantages:

1. Enhanced Bioavailability — An oral pharmacokinetic study comparing four lipid-based delivery systems (MCT oil, phosphatidylcholine-enriched oil, liposomal powder, and phosphatidylserine-based formulation) in rats demonstrated that phosphatidylserine (PS) yielded approximately 26% higher AUC₀–ₜ and 32% higher Cmax than the MCT-only control. Notably, elimination kinetics (K_el ≈ 0.08 h⁻¹; t1/2 ≈ 8 hours) remained consistent across all groups, confirming that increased systemic exposure resulted from improved absorption rather than changes in metabolism or clearance.

2. Enhanced Dispersion and Solubility — The liposomal formulation, supplied as a spray-dried powder containing mainly zwitterionic phosphatidylcholine and a small amount of negatively charged phosphatidylglycerol, reconstitutes easily in water to form a stable nanoscale dispersion. Dynamic light scattering showed a mean hydrodynamic diameter of 182.4 ± 4.1 nm and a PDI of 0.212 ± 0.016, with a ζ-potential of −34.7 ± 1.8 mV, indicating good colloidal stability in suspension.

3. Protection from Degradation — The phospholipid bilayer shields zeaxanthin from light, heat, and oxygen-induced degradation, preserving its intact molecular structure until reaching optimal absorption sites in the small intestine.

4. Enhanced Cellular Uptake — Phospholipid-rich mixed micelles can increase intestinal SR-BI-mediated carotenoid uptake by roughly 40%, supporting efficient cellular delivery.

Product Specifications

Key Features

• High Purity — Standardized to ≥40% zeaxanthin by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves a mean hydrodynamic diameter of 182.4 ± 4.1 nm with ζ-potential of −34.7 ± 1.8 mV, providing excellent colloidal stability. Phosphatidylserine-based liposomal delivery yields approximately 26% higher AUC and 32% higher Cmax compared to MCT-only controls.

• Macular Pigment Support — Zeaxanthin is selectively concentrated in the fovea, the center of the macula, where it forms the macular pigment alongside lutein and meso-zeaxanthin. This pigment absorbs high-energy blue light and protects photoreceptors from photo-oxidative damage.

• AREDS2-Backed Ratio — Formulated in a 5:1 ratio with lutein (10 mg lutein + 2 mg zeaxanthin), the optimal proportion backed by AREDS2, a major clinical trial by the National Eye Institute.

• Clinically Validated for AMD — AREDS2, a randomized, double-masked, placebo-controlled trial in 4,203 patients, demonstrated that the lutein/zeaxanthin formula reduced the risk of progression from intermediate to advanced AMD by approximately 25%. Patients with the lowest baseline dietary carotenoid intake who received the supplement showed a 26% reduction in risk for AMD progression.

• Antioxidant Defense — Zeaxanthin is a potent antioxidant that neutralizes reactive oxygen species and protects cellular membranes from lipid peroxidation.

• Water-Dispersible — Liposomal powder reconstitutes easily in water to form a stable nanoscale dispersion; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial products commonly recommend 2–10 mg of zeaxanthin per day. The AREDS2 clinical trial, a landmark study by the National Eye Institute, evaluated lutein (10 mg) + zeaxanthin (2 mg) supplementation in 4,203 patients with intermediate or late AMD in one eye. The study demonstrated an approximately 25% reduction in the risk of progression from intermediate to advanced AMD. Subgroup analysis showed that patients with the lowest baseline levels of lutein and zeaxanthin in their diets who added the supplement showed a 26% reduction in risk for AMD progression. For general eye health support, 2 mg daily is the standard AREDS2 dose, with higher doses up to 10 mg daily used in some cognitive and skin health studies. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.